Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 113, Issue 1, 2004, Pages 26-30

  Nap, Annemiek W ^a   Hamulyak, Karly ^b   Van Oerle, Rene ^b   Van Pampus, Lizzy C M ^b   Spaanderman, Marc E ^a   Damoiseaux, Jan ^b   Rosing, Jan ^c   Peeters, Louis L ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Activated protein C resistance; Fetal growth restriction; Pre eclampsia; Pregnancy; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL FACTOR;

ADULT; ANAMNESIS; ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTION TEST; HUMAN; INCIDENCE; NORMAL HUMAN; PLASMA; PREECLAMPSIA; PRENATAL GROWTH; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOPHILIA; UNIVERSITY HOSPITAL;

EID: 1442311013     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(03)00329-4     Document Type: Article

References (21)

1. Dekker G.A., De Vries J.I.P., Doelitzsch P.M., Huygens P.C., van Blomberg B.M., Jakobs C.et al. Underlying disorders associated with severe early-onset preeclampsia. Am. J. Obstet. Gynecol. 173:1995;1042-1048.
2. Spaanderman M.E.A., Ekhart T.H.A., de Leeuw P.W., Peeters L.L.H. Latent hemodynamic abnormalities in symptom-free women with a history of preeclampsia. Am. J. Obstet. Gynecol. 182:2000;101-107.
3. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., Haites N.E., Wilson B.J., Watson M.S.et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb. Haemost. 87:2002;779-785.
4. Kim Y.J., Williamson R.A., Murray J.C., Andrews J., Pietscher J.J., Peraud P.J.et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am. J. Obstet. Gynecol. 184:2001;1211-1217.
5. D'Elia A.V., Driul L., Giacomello R., Colaone R., Fabbro D., Di Leonardo C.et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol. Obstet. Invest. 53:2002;84-87.
6. Infante-Rivard C., Rivard G.E., Yotov W.V., Genin E., Guiget M., Weinberg C.et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N. Engl. J. Med. 347:2002;19-25.
7. De Visser M.C., Rosendaal F.R., Bertina R.M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 93:1999;1271-1276.
8. Dahlback B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1004-1008.
9. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
10. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Buller H.R., Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 346:1995;1593-1596.
11. Curvers J., Nap A.W., Thomassen C.M.L.G.D., Nienhuis S.J., Hamulyak K., Evers J.H.L.et al. Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway. Br. J. Haematol. 115:2001;400-407.
12. Nicolaes G.A.F., Thomassen M.C.L.G.D., Tans G., Rosing J., Hemker H.C. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coag. Fibrinol. 8:1997;28-38.
13. Report of the National High Blood Pressure Education Program, Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
14. Vinazzer H., Prangraz U. Protein C: comparison of different assays in normal and abnormal plasma samples. Thromb. Res. Suppl. 46:1987;1-8.
15. De Ronde H., Bertina R. Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb. Haemost. 72:1994;880-886.
16. Poort S., Bertina R., Vos H. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb. Haemost. 78:1997;1157-1158.
17. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J.et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547.
18. Rosing J., Middeldorp S., Curvers J., Thomassen C., Nicolaes G., Meijers J.et al. Acquired APC resistance and oral contraceptives: a randomized cross-over study of two low dose oral contraceptives. Lancet. 354:1999;2036-2040.
19. Clark P., Sattar N., Walker I.D., Greer I.A. The Glasgow outcome, APCR and lipid (GOAL) pregnancy study: significance of pregnancy associated activated protein C resistance. Thromb. Haemost. 85:2001;30-35.
20. Gulledge A.A., Rezaee F., Verheijen J.H., Lord S.T. A novel transgenic mouse model of hyperfibrinogenemia. Thromb. Haemost. 86:2001;511-516.
21. Von Dadelszen P., Magee L.A., Lee S.K., Stewart S.D., Simone C., Koren G.et al. Activated protein C in normal human pregnancy and pregnancy complicated by severe preeclampsia: a therapeutic opportunity? Crit. Care Med. 30:2002;1883-1892.